NAYA Biosciences Inc. (NAYA): Multiplikator forward rega marang pendapatan
NAYA Biosciences is enhancing its scientific image by integrating reproductive medicine with oncology. High R&D expenditures and stringent FDA oversight create significant barriers to entry for competitors. The closed nature of the biotech ecosystem through clinical phases stabilizes the base. The GURU.Markets system generates this chart, where the forward P/S ratio reflects valuation dynamics, and the indicator value reaches 0.30, signaling risks of asset overvaluation.
NAYA Biosciences Corp (NAYA) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- data utang lan likuiditas:
Total Utang marang Modal NAYA Biosciences|NAYA - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal NAYA Biosciences|NAYA - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku NAYA Biosciences Corp|NAYA - Utang jangka dawa|Utang jangka cendhak perusahaan NAYA Biosciences|Rasio cepet nayabiosciences.com
- rincian asil keuangan lan kelipatan valuasi:
NAYA - Penghasilan resik|Proyeksi bathi mangsa ngarep NAYA Biosciences|NAYA - Periode bali modal bisnis|Pangali Forward P/E NAYA Bio|NAYA - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan NAYA Biosciences Corp|NAYA - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) NAYA Biosciences|NAYA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan nayabiosciences.com|NAYA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep NAYA Biosciences
- data total pendapatan lan volume dodolan:
Analisis komprehensif perusahaan:NAYA (NAYA Biosciences Inc.)
This metric is calculated as the ratio of current market capitalization to projected revenue, allowing for an objective valuation of the asset relative to future cash flows. By analyzing the expected P/S ratio, an investor can align market expectations with the intensive R&D cycle of NAYA Biosciences (NAYA) focused on developing bispecific antibodies, determining a fair balance between the share price and the success of clinical drug validation.
Analisis pesaing
Multiplikator Forward P/S ONC (BeiGene)|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ascentage Pharma Corp|CGON: Multiplikator Forward P/S|urogen.com (URGN) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan BCAX|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|Rasio rega marang prakiraan pendapatan DCTH (Delcath Corp)|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake aurabiosciences.com (AURA)|CADL - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Accuray Inc|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TuHURA (HURA)|Multiplikator Forward P/S TARA|Rasio kapitalisasi marang dodolan sing dikarepake Fate Therapeutics Inc|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CSBR - Rasio rega marang prakiraan pendapatan|XBIT (XBiotech Inc.) - Kapitalisasi marang prakiraan pendapatan|CVM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Artiva ARTV|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|Rasio kapitalisasi marang dodolan sing dikarepake verupharma.com|Rasio rega marang prakiraan pendapatan Tempest Therapeutics, Inc. TPST|XLO: Kapitalisasi marang prakiraan pendapatan|Enochian BioSciences - Multiplikator Forward P/S|MURA - Multiplikator Forward P/S|KAPA (kairospharma.com) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OnKure Therapeutics (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S Curis Corp|Multiplikator Forward P/S APLM|Multiplikator forward rega marang pendapatan Tharimmune Corporation THAR|Multiplikator Forward P/S ADVB (Advanced Biomed)|Multiplikator Forward P/S genprex.com GNPX|CLDI - Rasio rega marang prakiraan pendapatan|SBFM (Sunshine Biopharma Inc.) - Kapitalisasi marang prakiraan pendapatan|XBIO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Salarius Pharma|PPBT (Purple Biotech) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AON AONC|Rasio rega marang prakiraan pendapatan BeiGene (BGNE)|CKPT (Checkpoint Therapeutics Inc.) - Rega forward marang dodolan|Elevation Oncology, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ICAD|Ikena - Multiplikator Forward P/S|notablelabs.com (NTBL) - Multiplikator forward rega marang pendapatan|VIRX (viracta.com) - Multiplikator forward rega marang pendapatan|MorphoSys Inc (MOR) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
